Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 1 (2006), Issue 8 (August)

1. HIV-related liver disease: infections versus drugs.
   Gastroenterol Clin North Am, 35(2): 487-505. [Abstract] [Full-text]
2. Treatment of hepatitis C infection.
   Gastroenterol Clin North Am, 35(2): 463-86. [Abstract] [Full-text]
3. Hepatitis B: the pathway to recovery through treatment.
   Gastroenterol Clin North Am, 35(2): 425-61, x. [Abstract] [Full-text]
4. Inhibition of oxidative stress and cytokine activity by curcumin in amelioration of endotoxin-induced experimental hepatoxicity in rodents.
   Clin Exp Immunol, 145(2): 313-21. [Abstract] [Full-text]
5. Anti-C1q antibodies in hepatitis C virus infection.
   Clin Exp Immunol, 145(2): 308-12. [Abstract] [Full-text]
6. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.
   Clin Gastroenterol Hepatol, 4(8): 936-62. [Abstract] [Full-text]
7. Chronic hepatitis C therapy: changing the rules of duration.
   Clin Gastroenterol Hepatol, 4(8): 963-71. [Abstract] [Full-text]
8. Treatment of chronic hepatitis B.
   Nat Clin Pract Gastroenterol Hepatol, 3(8): 446-58. [Abstract] [Full-text]
9. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index.
   J Intern Med, 260(2): 142-50. [Abstract] [Full-text]
10. Dramatic improvement of psoriatic erythroderma after acute hepatitis: analysis of cytokine synthesis capability in peripheral blood T cells.
    Br J Dermatol, 155(2): 455-9. [Abstract] [Full-text]
11. Expression of non-signaling membrane-anchored death receptors protects murine livers in different models of hepatitis.
    Hepatology, 44(2): 399-409. [Abstract] [Full-text]
12. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race.
    Hepatology, 44(2): 352-9. [Abstract] [Full-text]
13. Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population.
    Hepatology, 44(2): 341-51. [Abstract] [Full-text]
14. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
    Hepatology, 44(2): 360-7. [Abstract] [Full-text]
15. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment.
    Hepatology, 44(2): 335-40. [Abstract] [Full-text]
16. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection.
    Hepatology, 44(2): 326-34. [Abstract] [Full-text]
17. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
    Hepatology, 44(2): 318-25. [Abstract] [Full-text]
18. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
    Drug Alcohol Depend, 84(2): 188-94. [Abstract] [Full-text]
19. Altered CD45 expression in C77G carriers influences immune function and outcome of hepatitis C infection.
    J Med Genet, 43(8): 678-84. [Abstract] [Full-text]
20. Factors associated with exposure to hepatitis B virus in injection drug users.
    Drug Alcohol Depend, 84(2): 154-9. [Abstract] [Full-text]
21. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase.
    Clin Infect Dis, 43(5): 640-4. [Abstract] [Full-text]
22. Emerging co-infection of HIV and hepatitis B virus in far western Nepal.
    Trop Doct, 36(3): 186-7. [Abstract] [Full-text]
23. Hepatitis A, typhoid and malaria among travelers--surveillance data from Québec (Canada).
    J Travel Med, 13(4): 219-26. [Abstract] [Full-text]
24. Immunity to hepatitis A and hepatitis B in Indian and Chinese immigrants seen in a travel clinic in Massachusetts, United States.
    J Travel Med, 13(4): 212-8. [Abstract] [Full-text]
25. Interferon-alpha therapy in HBeAg-negative chronic hepatitis B: a long-term prospective study from north-western Greece.
    Aliment Pharmacol Ther, 24(3): 525-33. [Abstract] [Full-text]
26. Clinical features of Japanese male patients with type 1 autoimmune hepatitis.
    Aliment Pharmacol Ther, 24(3): 519-23. [Abstract] [Full-text]
27. Transient elastography: a valid alternative to biopsy in patients with chronic liver disease.
    Aliment Pharmacol Ther, 24(3): 513-8. [Abstract] [Full-text]
28. Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype.
    Aliment Pharmacol Ther, 24(3): 507-12. [Abstract] [Full-text]
29. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease.
    Aliment Pharmacol Ther, 24(3): 497-506. [Abstract] [Full-text]
30. Genetic predisposition of responsiveness to therapy for chronic hepatitis C.
    Pharmacogenomics, 7(5): 697-709. [Abstract] [Full-text]
31. Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapy.
    J Clin Microbiol, 44(8): 2983-7. [Abstract] [Full-text]
32. Multitypic hepatitis C virus infection identified by real-time nucleotide sequencing of minority genotypes.
    J Clin Microbiol, 44(8): 2779-84. [Abstract] [Full-text]
33. Chronic hepatitis B in hepatocarcinogenesis.
    Postgrad Med J, 82(970): 507-15. [Abstract] [Full-text]
34. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis.
    Autoimmunity, 39(4): 341-8. [Abstract] [Full-text]
35. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States.
    Gastroenterology, 131(2): 478-84. [Abstract] [Full-text]
36. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.
    Gastroenterology, 131(2): 470-7. [Abstract] [Full-text]
37. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
    Gastroenterology, 131(2): 451-60. [Abstract] [Full-text]
38. Analysis of prognostic factors in therapeutic responses to interferon in patients with chronic hepatitis C.
    Transl Res, 148(2): 79-86. [Abstract] [Full-text]
39. Reduced expression of the melanocortin-1 receptor in human liver during brain death.
    Neuroimmunomodulation, 13(1): 51-5. [Abstract] [Full-text]
40. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases.
    J Hepatol, 45(3): 355-60. [Abstract] [Full-text]
41. Is HCV infection associated with liver steatosis also in children?
    J Hepatol, 45(3): 350-4. [Abstract] [Full-text]
42. Co-infection of human parvovirus B19 in Vietnamese patients with hepatitis B virus infection.
    J Hepatol, 45(3): 361-9. [Abstract] [Full-text]
43. L-SIGN (CD209L) isoforms differently mediate trans-infection of hepatoma cells by hepatitis C virus pseudoparticles.
    J Gen Virol, 87: 2571-6. [Abstract] [Full-text]
44. Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B.
    Clin Vaccine Immunol, 13(8): 972-4. [Abstract] [Full-text]
45. Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks.
    Clin Vaccine Immunol, 13(8): 958-65. [Abstract] [Full-text]
46. Analysis of HLA-DQB1 gene polymorphisms in asymptomatic HBV carriers and chronic hepatitis B patients in the Chinese Han population.
    Int J Immunogenet, 33(4): 249-54. [Abstract] [Full-text]
47. Prevalence of hepatitis C virus infection among men who have sex with men at a Boston community health center and its association with markers of high-risk behavior.
    AIDS Patient Care STDS, 20(8): 557-64. [Abstract] [Full-text]
48. Rapid improvement of liver function in a patient with HIV and hepatitis B coinfection treated with lamivudine and tenofovir.
    Infection, 34(4): 234-5. [Abstract] [Full-text]
49. Difference of HBV genotype distribution between acute hepatitis and chronic hepatitis in Japan.
    Infection, 34(4): 201-7. [Abstract] [Full-text]
50. Improved long-term survival after liver resection for hepatocellular carcinoma in the modern era: retrospective study from HCV-endemic areas.
    World J Surg, 30(8): 1567-78. [Abstract] [Full-text]
51. HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction?
    J Antimicrob Chemother, 58(3): 496-501. [Abstract] [Full-text]
52. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C.
    Am J Transplant, 6(8): 1922-9. [Abstract] [Full-text]
53. Lipopolysaccharide-binding protein modulates hepatic damage and the inflammatory response after hemorrhagic shock and resuscitation.
    Am J Physiol Gastrointest Liver Physiol, 291(3): G456-63. [Abstract] [Full-text]
54. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users.
    J Viral Hepat, 13(8): 560-70. [Abstract] [Full-text]
55. The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1.
    J Viral Hepat, 13(8): 552-9. [Abstract] [Full-text]
56. Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection.
    J Viral Hepat, 13(8): 544-51. [Abstract] [Full-text]
57. Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation.
    J Viral Hepat, 13(8): 538-43. [Abstract] [Full-text]
58. Absence of HCV viral recombination following superinfection.
    J Viral Hepat, 13(8): 532-7. [Abstract] [Full-text]
59. Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection.
    J Viral Hepat, 13(8): 523-31. [Abstract] [Full-text]
60. Identification of T-cell epitopes associated with immunity within the surface protein of duck hepatitis B virus.
    J Viral Hepat, 13(8): 515-22. [Abstract] [Full-text]
61. Cytotoxic CD4 T cells in viral hepatitis.
    J Viral Hepat, 13(8): 505-14. [Abstract] [Full-text]
62. Viral kinetics in the treatment of chronic hepatitis C.
    J Viral Hepat, 13(8): 499-504. [Abstract] [Full-text]
63. Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan.
    BMC Infect Dis, 6: 101. [Abstract] [Full-text]
64. Treating viral hepatitis C: efficacy, side effects, and complications.
    Gut, 55(9): 1350-9. [Abstract] [Full-text]
65. Fulminant Epstein-Barr virus (EBV) hepatitis in a young immunocompetent subject.
    Med Mal Infect, 36(7): 396-8. [Abstract] [Full-text]
66. HIV, HBV, HCV, and syphilis co-infections among patients attending the STD clinics of district hospitals in Northern India.
    Int J Infect Dis, 10(5): 358-63. [Abstract] [Full-text]
67. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.
    Gut, 55(9): 1332-8. [Abstract] [Full-text]
68. Serologic profile in hepatitis B virus and hepatitis C virus in a Brazilian liver transplant waiting list.
    Transplant Proc, 38(6): 1920-1. [Abstract] [Full-text]
69. Impact of hepatitis C virus on renal transplantation: association with poor survival.
    Transplant Proc, 38(6): 1890-4. [Abstract] [Full-text]
70. Early intervention services for persons with HIV/AIDS and hepatitis C: a community health center perspective.
    Nurs Clin North Am, 41(3): 371-82, v-vi. [Abstract] [Full-text]
71. (-)-Epigallocatechin-3-gallate protects mice from concanavalin A-induced hepatitis through suppressing immune-mediated liver injury.
    Clin Exp Immunol, 145(3): 485-92. [Abstract] [Full-text]
72. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.
    Aliment Pharmacol Ther, 24(4): 593-600. [Abstract] [Full-text]
73. Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects.
    Aliment Pharmacol Ther, 24(4): 585-91. [Abstract] [Full-text]
74. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong.
    Aliment Pharmacol Ther, 24(4): 573-83. [Abstract] [Full-text]
75. Low density lipoprotein receptor transcripts correlates with liver hepatitis C virus RNA in patients with alcohol consumption.
    J Viral Hepat, 13(9): 633-42. [Abstract] [Full-text]
76. Increased intrahepatic and circulating levels of endoglin, a TGF-beta1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis.
    J Viral Hepat, 13(9): 625-32. [Abstract] [Full-text]
77. Association of TNF-alpha promoter polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population.
    J Viral Hepat, 13(9): 618-24. [Abstract] [Full-text]
78. Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C.
    J Viral Hepat, 13(9): 613-7. [Abstract] [Full-text]
79. Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-centre randomized study.
    J Viral Hepat, 13(9): 597-604. [Abstract] [Full-text]
80. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
    J Viral Hepat, 13(9): 591-6. [Abstract] [Full-text]
81. Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma.
    J Viral Hepat, 13(9): 574-81. [Abstract] [Full-text]
82. Hepatitis C - contamination of toothbrushes: myth or reality?
    J Viral Hepat, 13(9): 571-3. [Abstract] [Full-text]
83. Oxidative stress in hepatitis C infected end-stage renal disease subjects.
    BMC Infect Dis, 6: 114. [Abstract] [Full-text]
84. Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center.
    Eur J Clin Microbiol Infect Dis, 25(8): 527-31. [Abstract] [Full-text]
85. Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison.
    BMC Public Health, 6: 170. [Abstract] [Full-text]
86. No association between hepatitis C virus seropositivity and acute myocardial infarction.
    Clin Infect Dis, 43(6): e53-6. [Abstract] [Full-text]
87. Influence of Helicobacter pylori infection on iron accumulation in hepatitis C.
    Liver Int, 26(7): 827-33. [Abstract] [Full-text]
88. Potential role of hepatic progenitor cells expression in cases of chronic hepatitis C and their relation to response to therapy: a clinicopathologic study.
    Liver Int, 26(7): 817-26. [Abstract] [Full-text]
89. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.
    Liver Int, 26(7): 805-10. [Abstract] [Full-text]
90. Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center.
    Liver Int, 26(7): 796-804. [Abstract] [Full-text]
91. Genetic variability in the precore and core promoter regions of hepatitis B virus strains in Karachi.
    BMC Gastroenterol, 6: 20. [Abstract] [Full-text]
92. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.
    Clin Biochem, 39(7): 715-21. [Abstract] [Full-text]
93. Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids.
    Intervirology, 49(5): 274-80. [Abstract] [Full-text]
94. Sequential accumulation of the basal core promoter and the precore mutations in the progression of hepatitis B virus-related chronic liver disease.
    Intervirology, 49(5): 266-73. [Abstract] [Full-text]
95. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis.
    Nephron Clin Pract, 104(1): c1-6. [Abstract] [Full-text]
96. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
    Clin Cancer Res, 12(16): 4867-71. [Abstract] [Full-text]
97. Favorable outcome of liver transplantation despite a high hepatitis B virus replication: beyond the limits?
    Transpl Infect Dis, 8(3): 182-4. [Abstract] [Full-text]
98. Herpes simplex virus hepatitis: expanding the spectrum of disease.
    Transpl Infect Dis, 8(3): 171-6. [Abstract] [Full-text]
99. Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients.
    Autoimmun Rev, 5(7): 493-8. [Abstract] [Full-text]
100. Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment.
     J Subst Abuse Treat, 31(2): 195-202. [Abstract] [Full-text]
101. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C.
     Eur J Clin Invest, 36: 67-70. [Abstract] [Full-text]
102. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link?
     J Intern Med, 260(3): 255-62. [Abstract] [Full-text]
103. Improving anti-hepatitis C virus therapy.
     Expert Opin Biol Ther, 6(9): 923-33. [Abstract] [Full-text]
104. New developments in the treatment of chronic hepatitis B.
     Expert Opin Biol Ther, 6(9): 913-21. [Abstract] [Full-text]
105. Recent development of therapeutics for chronic HCV infection.
     Antiviral Res, 71(2): 351-62. [Abstract] [Full-text]
106. Soluble egg antigen of Schistosoma Haematobium induces HCV replication in PBMC from patients with chronic HCV infection.
     BMC Infect Dis, 6: 91. [Abstract] [Full-text]
107. Antiviral therapy of chronic hepatitis B.
     Antiviral Res, 71(2): 206-15. [Abstract] [Full-text]
108. Perinatal hepatitis C virus infection: diagnosis and management.
     Arch Dis Child, 91(9): 781-5. [Abstract] [Full-text]
109. Hypertrichosis lanuginosa acquisita associated with autoimmune hepatitis.
     J Dermatol, 33(8): 574-6. [Abstract] [Full-text]
110. Negative evaluation of a pathergy test in hepatitis B surface antigen carriers.
     J Dermatol, 33(8): 547-9. [Abstract] [Full-text]
111. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region.
     Eur J Haematol, 77(3): 255-8. [Abstract] [Full-text]
112. Vertical transmission of fatal Rift Valley fever in a newborn.
     Ann Trop Paediatr, 26(3): 251-3. [Abstract] [Full-text]
113. The changing prevalence of hepatitis B virus infection among men who have sex with men who attended a sexually transmitted infections clinic in Edinburgh, Scotland between 1989 and 2003.
     Int J STD AIDS, 17(8): 539-42. [Abstract] [Full-text]
114. Autoimmune thrombocytopenia induced by PEG-IFN-alpha plus ribavirin in hepatitis C.
     Platelets, 17(5): 340-3. [Abstract] [Full-text]
115. Association between hepatitis A virus and Helicobacter pylori in a developing country: the saga continues.
     J Gastroenterol Hepatol, 21(10): 1615-21. [Abstract] [Full-text]
116. Does co-infection with multiple viruses adversely influence the course and outcome of sporadic acute viral hepatitis in children?
     J Gastroenterol Hepatol, 21(10): 1533-7. [Abstract] [Full-text]
117. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
     J Gastroenterol Hepatol, 21(10): 1525-32. [Abstract] [Full-text]
118. Prediction of the prognosis in patients with acute-on-chronic hepatitis using the MELD scoring system.
     J Gastroenterol Hepatol, 21(10): 1519-24. [Abstract] [Full-text]
119. More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis.
     Am J Gastroenterol, 101(8): 1817-23. [Abstract] [Full-text]
120. Hepatitis C infection is associated with depressive symptoms in HIV-infected adults with alcohol problems.
     Am J Gastroenterol, 101(8): 1804-10. [Abstract] [Full-text]
121. Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured?
     Am J Gastroenterol, 101(8): 1811-6. [Abstract] [Full-text]
122. Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients.
     J Gastroenterol, 41(7): 693-701. [Abstract] [Full-text]
123. Polyneuropathy with demyelinating features in mixed cryoglobulinemia with hepatitis C virus infection.
     Eur J Neurol, 13(9): 937-41. [Abstract] [Full-text]
124. Chronic ethanol consumption inhibits hepatic natural killer cell activity and accelerates murine cytomegalovirus-induced hepatitis.
     Alcohol Clin Exp Res, 30(9): 1615-23. [Abstract] [Full-text]
125. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems.
     Alcohol Clin Exp Res, 30(9): 1520-6. [Abstract] [Full-text]
126. Population beliefs about the efficacy of injections in Pakistan's Sindh province.
     Public Health, 120(9): 824-33. [Abstract] [Full-text]
127. Chronic Hepatitis B and C--current treatment and future therapeutic prospects.
     Wien Med Wochenschr, 156(13): 391-6. [Abstract] [Full-text]
128. The natural history of childhood-acquired hepatitis C infection in patients with inherited bleeding disorders.
     Transfusion, 46(8): 1360-6. [Abstract] [Full-text]
129. How does hepatitis C virus enter cells?
     FEBS J, 273(17): 3871-85. [Abstract] [Full-text]
130. Association of genetic polymorphism of low-density lipoprotein receptor with chronic viral hepatitis C infection in Han Chinese.
     J Med Virol, 78(10): 1289-95. [Abstract] [Full-text]
131. Low HBV-DNA levels in end-stage renal disease patients with HBeAg-negative chronic hepatitis B.
     J Med Virol, 78(10): 1284-8. [Abstract] [Full-text]
132. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.
     J Med Virol, 78(10): 1276-83. [Abstract] [Full-text]
133. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
     J Med Virol, 78(10): 1304-11. [Abstract] [Full-text]
134. Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users.
     J Med Virol, 78(10): 1296-303. [Abstract] [Full-text]
135. A novel mutation of varicella-zoster virus associated to fatal hepatitis.
     J Clin Virol, 37(1): 72-4. [Abstract] [Full-text]
136. Distribution of HCV genotypes in patients with end-stage renal disease according to type of dialysis treatment.
     Dig Dis Sci, 51(8): 1420-5. [Abstract] [Full-text]
137. Comprehensive analysis of differential gene expression profiles on diclofenac-induced acute mouse liver injury and recovery.
     Toxicol Lett, 166(1): 77-87. [Abstract] [Full-text]
138. Prevalent HBV genotypes and subtypes in a South Indian population.
     J Clin Virol, 37(1): 58-64. [Abstract] [Full-text]
139. Treatment of hepatitis C in hemophiliacs.
     Am J Hematol, 81(9): 696-702. [Abstract] [Full-text]
140. Sensitivities of gel entrapped hepatocytes in hollow fibers to hepatotoxic drug.
     Toxicol Lett, 166(1): 19-26. [Abstract] [Full-text]
141. Antimutagenic activity of methanolic extract of Ganoderma lucidum and its effect on hepatic damage caused by benzo[a]pyrene.
     J Ethnopharmacol, 107(2): 297-303. [Abstract] [Full-text]
142. Hepatoprotective effect of extracts from Pergularia daemia Forsk.
     J Ethnopharmacol, 107(2): 164-8. [Abstract] [Full-text]
143. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon.
     Scand J Gastroenterol, 41(9): 1087-94. [Abstract] [Full-text]
144. Polymorphism of interferon-gamma gene at position +874 and clinical characteristics of chronic hepatitis C.
     Transl Res, 148(3): 128-33. [Abstract] [Full-text]
145. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
     Transl Res, 148(3): 120-7. [Abstract] [Full-text]
146. Beneficial effect of hesperidin on lipopolysaccharide-induced hepatotoxicity.
     Toxicology, 226(2): 152-60. [Abstract] [Full-text]
147. Toxicophores: investigations in drug safety.
     Toxicology, 226(1): 1-11. [Abstract] [Full-text]
148. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.
     Clin Infect Dis, 43(7): 904-10. [Abstract] [Full-text]
149. Social structural and behavioral underpinnings of hyperendemic hepatitis C virus transmission in drug injectors.
     J Infect Dis, 194(6): 764-72. [Abstract] [Full-text]
150. Hepatitis E indigenous to economically developed countries: to what extent a zoonosis?
     Curr Opin Infect Dis, 19(5): 460-6. [Abstract] [Full-text]
151. Vaccination against hepatitis A and B: developments, deployment and delusions.
     Curr Opin Infect Dis, 19(5): 456-9. [Abstract] [Full-text]
152. Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism.
     J Virol, 80(18): 9144-50. [Abstract] [Full-text]
153. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis.
     Cancer Invest, 24(5): 548-52. [Abstract] [Full-text]
154. Engagement, reciprocity and advocacy: ethical harm reduction practice in research with injecting drug users.
     Drug Alcohol Rev, 25(5): 419-23. [Abstract] [Full-text]
155. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study.
     Liver Transpl, 12(9): 1381-9. [Abstract] [Full-text]
156. Adefovir dipivoxyl for the treatment of delta-related liver cirrhosis.
     Ann Pharmacother, 40(9): 1681-4. [Abstract] [Full-text]
157. Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images.
     J Magn Reson Imaging, 24(3): 690-4. [Abstract] [Full-text]
158. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan.
     Int J Cancer, 119(8): 1946-52. [Abstract] [Full-text]
159. Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study.
     Dig Dis Sci, 51(7): 1183-9. [Abstract] [Full-text]
160. Hepatitis delta virus super-infection in a co-infected patient with the human immunodeficiency virus type 1 and a surface antigen-negative hepatitis B virus variant.
     Int J STD AIDS, 17(9): 635-8. [Abstract] [Full-text]
161. Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users.
     Int J STD AIDS, 17(9): 621-6. [Abstract] [Full-text]
162. Drug abuse, innate immunity and hepatitis C virus.
     Rev Med Virol, 16(5): 311-27. [Abstract] [Full-text]

© 2006-2008 Hepatitis Research Today. All Rights Reserved.